Rituximab, a monoclonal antibody directed against the CD20 molecule found on pre-B cells and mature B cells (but not on plasma cells), was introduced in the late 1990s for the treatment of non ...

The following is a summary of “Chronic graft-versus-host disease myelitis successfully treated with rituximab,” published in ...

An additional rituximab dose in patients with pemphigus and at least one predictor of relapse may reduce the relapse rate, according to the results of a multicenter French study.

The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...

MSD began worldwide recruitment for the trial and subjects are currently being enrolled. In the randomised trial, the ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

The FDA has approved Genentech’s subcutaneous version of the cancer drug rituximab, allowing for a more convenient injection lasting minutes, rather than several hours. Branded as Rituxan Hycela ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal ...

ASH 2024 featured practice-changing studies in lymphoid malignancies, including tafasitamab’s impact in FL, ibrutinib’s OS benefit in MCL, and promising epcoritamab data in CLL.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Findings showed acalabrutinib with bendamustine and rituximab (BR) reduced the risk of disease progression or death by 27% compared with placebo plus BR. The Food and Drug Administration (FDA ...